Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit enhanced neutralization upon combinatorial testing. Read More
Sanofi, GSK get $2.1B for COVID-19 vaccine
The U.S. government will provide up to $2.1 billion to Sanofi and GlaxoSmithKline (GSK) for the development and manufacturing of a recombinant protein-based COVID-19 vaccine. Read More
Enterome begins trial for microbiome-based immunotherapy
Clinical-stage biopharmaceutical company Enterome has begun its first clinical trial for E02401, a microbiome-based cancer immunotherapy candidate. Read More
PanCan, GeneCentric partner on precision medicine for pancreatic cancer
The Pancreatic Cancer Action Network (PanCan) and GeneCentric Therapeutics have partnered to conduct research on RNA-based molecular technologies to predict pancreatic cancer disease progression and drug response. Read More
Direct Biologics begins phase II trial for COVID-19 ExoFlo therapy
Regenerative medical products manufacturer Direct Biologics has won approval from the U.S. Food and Drug Administration to study its ExoFlo therapy in a clinical trial with COVID-19 patients. Read More
Cancer research groups partner for liquid biopsy trial
The Cancer Research Institute and the Mark Foundation for Cancer Research have partnered on a clinical trial to evaluate whether a novel liquid biopsy diagnostic can assess immune response in cancer patients. Read More
SAB begins seasonal flu immunotherapy clinical trial
SAB Biotherapeutics has begun a phase I clinical trial evaluating SAB-176 for the treatment of seasonal influenza. Read More
J&J reports positive preclinical results for COVID-19 vaccine
Johnson & Johnson reported that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 in preclinical studies. Read More
Inovio reports long-term positive results for COVID-19 vaccine
Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, INO-4800. The vaccine protected the animals 13 weeks after vaccinations and mediated T- and B-cell immune responses, according to the firm. Read More
Intravacc, Celonic to jointly develop COVID-19 vaccine
Vaccine development firm Intravacc and biopharmaceutical contract development and manufacturing organization Celonic are teaming up to develop a COVID-19 vaccine. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
